{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:10:24Z","timestamp":1774566624416,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1993,1,1]],"date-time":"1993-01-01T00:00:00Z","timestamp":725846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1993,1,1]],"date-time":"1993-01-01T00:00:00Z","timestamp":725846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[1993,1]]},"DOI":"10.1378\/chest.103.1.209","type":"journal-article","created":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T13:28:23Z","timestamp":1194442103000},"page":"209-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural Effusion"],"prefix":"10.1016","volume":"103","author":[{"given":"Philippe","family":"Astoul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Regis","family":"Viallat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Claude","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Brandely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.103.1.209_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1988.6.3.527","article-title":"Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers","volume":"6","author":"Alberts","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.103.1.209_bib2","series-title":"Asbestos-related malignancy","first-page":"232","article-title":"Surgical treatment of pleural mesothelioma","author":"Schemin","year":"1987"},{"key":"10.1378\/chest.103.1.209_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0007-0971(83)90068-2","article-title":"Malignant mesothelioma: review of 4710 published cases","volume":"77","author":"Hillerdal","year":"1983","journal-title":"Br J Dis Chest"},{"key":"10.1378\/chest.103.1.209_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0002-9343(77)90154-1","article-title":"Carcinomatous involvement of the pleura","volume":"63","author":"Chernow","year":"1977","journal-title":"Am J Med"},{"key":"10.1378\/chest.103.1.209_bib5","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","article-title":"Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose rIL-2","volume":"161","author":"Rosenberg","year":"1985","journal-title":"J Exp Med"},{"key":"10.1378\/chest.103.1.209_bib6","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1001\/jama.1986.03380220083027","article-title":"High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings","volume":"256","author":"Lotze","year":"1986","journal-title":"JAMA"},{"key":"10.1378\/chest.103.1.209_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.1988.6.3.403","article-title":"Cancer therapy with interleuldn-2: immunologic manipulations can mediate the regression of cancer in humans","volume":"6","author":"Rosenberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.103.1.209_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/1097-0142(19900201)65:3+<800::AID-CNCR2820651328>3.0.CO;2-Y","article-title":"Lymphokines and cytokines as cancer treatment: immunotherapy realized","volume":"65","author":"Borden","year":"1990","journal-title":"Cancer"},{"key":"10.1378\/chest.103.1.209_bib9","first-page":"1823","article-title":"The fate of interleukin-2 after in vivo administration","volume":"130","author":"Donohve","year":"1983","journal-title":"J Immunol"},{"key":"10.1378\/chest.103.1.209_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","article-title":"In vivo administration of purified human IL-2: I. Half-life and immunologic effects of the Jurkat cell line-derived IL-2","volume":"1","author":"Lotze","year":"1985","journal-title":"J Immunol"},{"key":"10.1378\/chest.103.1.209_bib11","first-page":"561","article-title":"Systemic administration of recombinant human interleuldn-2 in mice","volume":"3","author":"Chang","year":"1984","journal-title":"J Biol Response Mod"},{"key":"10.1378\/chest.103.1.209_bib12","first-page":"2784","article-title":"Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleuldn-2","volume":"46","author":"Ettinghausen","year":"1986","journal-title":"Cancer Res"},{"key":"10.1378\/chest.103.1.209_bib13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM198704093161502","article-title":"Constant-infusion rIL-2 in adoptive immunotherapy in advanced cancer","volume":"316","author":"West","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.103.1.209_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/1097-0142(19890815)64:4<783::AID-CNCR2820640402>3.0.CO;2-F","article-title":"A phase I study of IL-2 in children with cancer and evaluation of clinical and immunologic status during therapy","volume":"64","author":"Nasr","year":"1989","journal-title":"Cancer"},{"key":"10.1378\/chest.103.1.209_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1989.7.1.7","article-title":"Ognibene FP Cardiorespiratory effects of immunotherapy with interleukin 2","volume":"7","author":"Lee","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.103.1.209_bib16","first-page":"2184","article-title":"Induction of lymphokine-activated killer cells by intrapleural instillations of rIL-2 in patients with malignant pleurisy due to lung cancer","volume":"44","author":"Yasumoto","year":"1987","journal-title":"Cancer Res"},{"key":"10.1378\/chest.103.1.209_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/ajrccm\/139.4.897","article-title":"Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by rIL-2","volume":"139","author":"Robinson","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.103.1.209_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1164\/ajrccm\/139.6.1369","article-title":"Lysis of human malignant mesothelioma cells by natural killer and lymphokine-activated killer cells","volume":"139","author":"Manning","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.103.1.209_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thx.31.1.15","article-title":"Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura","volume":"31","author":"Butchard","year":"1976","journal-title":"Thorax"},{"key":"10.1378\/chest.103.1.209_bib20","series-title":"Handbook for reporting results of cancer treatment: WHO Offset publication","first-page":"48","year":"1979"},{"key":"10.1378\/chest.103.1.209_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0022-1759(86)90015-3","article-title":"Large scale production of human lymphokine-activated killer cells for use in adoptive immunotherapy","volume":"88","author":"Muul","year":"1986","journal-title":"J Immunol Methods"},{"key":"10.1378\/chest.103.1.209_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cell and interleukin 2 or high dose interleukin 2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.103.1.209_bib23","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.103.1.209_bib24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.6332379","article-title":"Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleuldn-2","volume":"225","author":"Mule","year":"1984","journal-title":"Science"},{"key":"10.1378\/chest.103.1.209_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.1983.15","article-title":"Clearance rates and systemic effects of intravenously administered interleuldn-2 (rIL-2) containing preparations in human subjects","volume":"47","author":"Bindon","year":"1983","journal-title":"Br J Cancer"},{"key":"10.1378\/chest.103.1.209_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.2910340312","article-title":"Tumor regression after intralesional injection of interleuldn-2 (IL-2) in bladder cancer: preliminary report","volume":"34","author":"Pizza","year":"1984","journal-title":"Int J Cancer"},{"key":"10.1378\/chest.103.1.209_bib27","first-page":"100","article-title":"Toxicity of interferon and interleukin","volume":"8","author":"Fent","year":"1987","journal-title":"TIPS"},{"key":"10.1378\/chest.103.1.209_bib28","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1001\/jama.1986.03380220107034","article-title":"On lymphokines, cytokines and breakthroughs","volume":"256","author":"Moertel","year":"1986","journal-title":"JAMA"},{"key":"10.1378\/chest.103.1.209_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archsurg.1986.01400120019002","article-title":"Intraperitoneal administration of interleuldn-2 in patients with cancer","volume":"121","author":"Lotze","year":"1986","journal-title":"Arch Surg"},{"key":"10.1378\/chest.103.1.209_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ijc.2910410409","article-title":"Survival patterns for malignant mesothelioma: the seer experience","volume":"41","author":"Spirtas","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1378\/chest.103.1.209_bib31","series-title":"Asbestos-related malignancy","first-page":"301","article-title":"Thoracoscopy in diagnosis, prognosis and treatment of mesothelioma","author":"Boutin","year":"1987"},{"key":"10.1378\/chest.103.1.209_bib32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/1097-0142(197612)38:6<2481::AID-CNCR2820380637>3.0.CO;2-9","article-title":"Pleural mesothelioma","volume":"38","author":"Wanebo","year":"1976","journal-title":"Cancer"},{"key":"10.1378\/chest.103.1.209_bib33","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W","article-title":"Malignant mesothelioma of pleura","volume":"49","author":"Brenner","year":"1982","journal-title":"Cancer"},{"key":"10.1378\/chest.103.1.209_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF01728801","article-title":"Malignant mesothelioma of the pleura","volume":"86","author":"Calavrezos","year":"1988","journal-title":"Klin Wochenschr"},{"key":"10.1378\/chest.103.1.209_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0002-9343(80)90103-5","article-title":"Multimodality therapy for malignant mesothelioma based on a study of natural history","volume":"68","author":"Antman","year":"1980","journal-title":"Am J Med"},{"key":"10.1378\/chest.103.1.209_bib36","first-page":"438","article-title":"Malignant mesothelioma: current status and future prospects","volume":"74","author":"Aisner","year":"1980","journal-title":"Chest"},{"key":"10.1378\/chest.103.1.209_bib37","first-page":"711","article-title":"Phase II high dose cisplatin in patients with malignant mesothelioma","volume":"69","author":"Minzer","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1378\/chest.103.1.209_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/thx.39.4.255","article-title":"Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients","volume":"39","author":"Law","year":"1984","journal-title":"Thorax"},{"key":"10.1378\/chest.103.1.209_bib39","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8","article-title":"Activity of intrapleural recombinant interferon gamma in malignant mesothelioma","volume":"67","author":"Boutin","year":"1991","journal-title":"Cancer"},{"key":"10.1378\/chest.103.1.209_bib40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1378\/chest.99.4.911","article-title":"Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly (L-lactic acid) microspheres","volume":"99","author":"Ike","year":"1991","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216383246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216383246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:44:10Z","timestamp":1757922250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369216383246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,1]]}},"alternative-id":["S0012369216383246"],"URL":"https:\/\/doi.org\/10.1378\/chest.103.1.209","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[1993,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural Effusion","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.103.1.209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1993 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}